Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa

Masato Akiyama, Yasuhiro Ikeda, Noriko Yoshida, Shoji Notomi, yusuke murakami, Toshio Hisatomi, Hiroshi Enaida, Tatsuro Ishibashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose To evaluate the therapeutic effect of topical unoprostone isopropyl (unoprostone) on patients with retinitis pigmentosa (RP). Methods Forty patients with typical forms of RP were included in the study. Seventeen of 40 patients were treated with 0.12% topical unoprostone twice daily in a randomly selected eye. Patients underwent follow-up examinations every 3 months after treatment. The efficacy of the treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 programme). Moreover, 12 RP patients who were included this study and 12 normal subjects were evaluated in terms of their macular blood flow of both eyes after instillation of unoprostone using the laser speckle method. Results One year after treatment, the 'macular sensitivity', calculated by HFA as the average sensitivity of the central 12 points, was preserved in the fellow eyes as well as the unoprostone-treated eyes. On the other hand, that in the eyes of the control RP patient was significantly decreased. Moreover, there were significantly greater improvements of the 'macular sensitivity' in the unoprostone-treated eyes than the fellow eyes. The change ratios of macular blood flow obtained from both RP patients and normal subjects were significantly increased in both the treated and the fellow eyes. No severe side-effects were observed. Conclusions These results demonstrate that topical unoprostone might have a therapeutic efficacy in patients with RP as a consequence of the macular blood flow improvement as well as its direct neuroprotective effect.

Original languageEnglish
JournalActa Ophthalmologica
Volume92
Issue number3
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Retinitis Pigmentosa
Therapeutics
isopropyl unoprostone
Neuroprotective Agents
Therapeutic Uses
Visual Fields
Visual Acuity
Lasers

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa. / Akiyama, Masato; Ikeda, Yasuhiro; Yoshida, Noriko; Notomi, Shoji; murakami, yusuke; Hisatomi, Toshio; Enaida, Hiroshi; Ishibashi, Tatsuro.

In: Acta Ophthalmologica, Vol. 92, No. 3, 01.01.2014.

Research output: Contribution to journalArticle

@article{c795c608fcce4b1691d438f419de9f1e,
title = "Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa",
abstract = "Purpose To evaluate the therapeutic effect of topical unoprostone isopropyl (unoprostone) on patients with retinitis pigmentosa (RP). Methods Forty patients with typical forms of RP were included in the study. Seventeen of 40 patients were treated with 0.12{\%} topical unoprostone twice daily in a randomly selected eye. Patients underwent follow-up examinations every 3 months after treatment. The efficacy of the treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 programme). Moreover, 12 RP patients who were included this study and 12 normal subjects were evaluated in terms of their macular blood flow of both eyes after instillation of unoprostone using the laser speckle method. Results One year after treatment, the 'macular sensitivity', calculated by HFA as the average sensitivity of the central 12 points, was preserved in the fellow eyes as well as the unoprostone-treated eyes. On the other hand, that in the eyes of the control RP patient was significantly decreased. Moreover, there were significantly greater improvements of the 'macular sensitivity' in the unoprostone-treated eyes than the fellow eyes. The change ratios of macular blood flow obtained from both RP patients and normal subjects were significantly increased in both the treated and the fellow eyes. No severe side-effects were observed. Conclusions These results demonstrate that topical unoprostone might have a therapeutic efficacy in patients with RP as a consequence of the macular blood flow improvement as well as its direct neuroprotective effect.",
author = "Masato Akiyama and Yasuhiro Ikeda and Noriko Yoshida and Shoji Notomi and yusuke murakami and Toshio Hisatomi and Hiroshi Enaida and Tatsuro Ishibashi",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/aos.12293",
language = "English",
volume = "92",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa

AU - Akiyama, Masato

AU - Ikeda, Yasuhiro

AU - Yoshida, Noriko

AU - Notomi, Shoji

AU - murakami, yusuke

AU - Hisatomi, Toshio

AU - Enaida, Hiroshi

AU - Ishibashi, Tatsuro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose To evaluate the therapeutic effect of topical unoprostone isopropyl (unoprostone) on patients with retinitis pigmentosa (RP). Methods Forty patients with typical forms of RP were included in the study. Seventeen of 40 patients were treated with 0.12% topical unoprostone twice daily in a randomly selected eye. Patients underwent follow-up examinations every 3 months after treatment. The efficacy of the treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 programme). Moreover, 12 RP patients who were included this study and 12 normal subjects were evaluated in terms of their macular blood flow of both eyes after instillation of unoprostone using the laser speckle method. Results One year after treatment, the 'macular sensitivity', calculated by HFA as the average sensitivity of the central 12 points, was preserved in the fellow eyes as well as the unoprostone-treated eyes. On the other hand, that in the eyes of the control RP patient was significantly decreased. Moreover, there were significantly greater improvements of the 'macular sensitivity' in the unoprostone-treated eyes than the fellow eyes. The change ratios of macular blood flow obtained from both RP patients and normal subjects were significantly increased in both the treated and the fellow eyes. No severe side-effects were observed. Conclusions These results demonstrate that topical unoprostone might have a therapeutic efficacy in patients with RP as a consequence of the macular blood flow improvement as well as its direct neuroprotective effect.

AB - Purpose To evaluate the therapeutic effect of topical unoprostone isopropyl (unoprostone) on patients with retinitis pigmentosa (RP). Methods Forty patients with typical forms of RP were included in the study. Seventeen of 40 patients were treated with 0.12% topical unoprostone twice daily in a randomly selected eye. Patients underwent follow-up examinations every 3 months after treatment. The efficacy of the treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 programme). Moreover, 12 RP patients who were included this study and 12 normal subjects were evaluated in terms of their macular blood flow of both eyes after instillation of unoprostone using the laser speckle method. Results One year after treatment, the 'macular sensitivity', calculated by HFA as the average sensitivity of the central 12 points, was preserved in the fellow eyes as well as the unoprostone-treated eyes. On the other hand, that in the eyes of the control RP patient was significantly decreased. Moreover, there were significantly greater improvements of the 'macular sensitivity' in the unoprostone-treated eyes than the fellow eyes. The change ratios of macular blood flow obtained from both RP patients and normal subjects were significantly increased in both the treated and the fellow eyes. No severe side-effects were observed. Conclusions These results demonstrate that topical unoprostone might have a therapeutic efficacy in patients with RP as a consequence of the macular blood flow improvement as well as its direct neuroprotective effect.

UR - http://www.scopus.com/inward/record.url?scp=84899411683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899411683&partnerID=8YFLogxK

U2 - 10.1111/aos.12293

DO - 10.1111/aos.12293

M3 - Article

VL - 92

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 3

ER -